Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.

Expert review of hematology - 1 Oct 2024

Shahswar Rabia, Ganser Arnold

Abstract excerpt

INTRODUCTION: The combined use of the BCL-2 inhibitor venetoclax with azacitidine now is the standard of care for patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy with outcomes exceeding those achieved with hypomethylating agents alone. Venetoclax in combination with intensive chemotherapy is also increasingly used both as frontline as well as salvage therapy. However, resistance to and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Leukemia, Myeloid, Acute

Share to Proto-Oncogene Proteins c-bcl-2

Share to Recurrence

Share to Salvage Therapy

Share to Sulfonamides

Source

Identifiers

PMID: 39246164
DOI: 10.1080/17474086.2024.2402283

Genes

FLT3
IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.PMID 39246164Read ↗

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read ↗

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity Read ↗

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity Read ↗

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity Read ↗

Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity Read ↗

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemiaSemantic proximity Read ↗

Venetoclax resistance: mechanistic insights and future strategiesSemantic proximity Read ↗

Venetoclax Resistance in Acute Myeloid LeukemiaSemantic proximity Read ↗

The Spectrum of Venetoclax-Based Treatments in Acute Myeloid LeukemiaSemantic proximity Read ↗

Venetoclax combined with hypomethylating agents and the CAG regimen (DCAG) in relapsed/refractory AML: A single- center clinical trialSemantic proximity Read ↗

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity Read ↗

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.